IM Cannabis

IMCC

Market cap $8.13M

TORONTO and GLIL YAM, Israel , Nov. 13, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ: IMCC), an international medical cannabis company, announced its financial results today for the third quarter and nine months ended September 30, 2025. All amounts are reported in Canadian dollars and compared to the quarter and nine months ended September 30, 2024, unless otherwise stated.

TORONTO and GLIL YAM, Israel , Nov. 6, 2025 /PRNewswire/ -- IM Cannabis Corp. (NASDAQ: IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the third quarter 2025 ended September 30, 2025, on Thursday, November 13, 2025, before the market opens. About IM Cannabis Corp. IMC (Nasdaq: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets.

TORONTO and GLIL YAM, Israel , Oct. 29, 2025 /PRNewswire/ -- IM Cannabis Corp. (NASDAQ: IMCC) (the "Company", "IM Cannabis", or "IMC"), a leading international medical cannabis company with operations in Israel and Germany, today announced that Uri Birenberg, the Company's Chief Financial Officer, will be stepping down from his role  for personal reasons. Mr. Birenberg is expected to continue serving as Chief Financial Officer until January 5, 2026, or such earlier date as may be determined by the Company, and will assist in a structured transition process until a successor is appointed.

The cannabis industry continues to evolve as investors prepare for potential U.S. federal reform and international market expansion. Despite short-term volatility, global demand for both medical and recreational cannabis is increasing. Analysts project the U.S. cannabis market could exceed $50 billion by 2030, driven by growing legalization efforts and shifting consumer attitudes. However, navigating this emerging sector requires careful attention to fundamentals, technical analysis, and disciplined risk management. Traders should focus on companies that show financial stability, market expansion, and consistent revenue growth before the next wave of legalization news.

TORONTO and GLIL YAM, Israel , Oct. 23, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ: IMCC), a leading medical cannabis company with operations in Israel and Germany, today announced the signing of a non-binding indicative term sheet for a proposed securities exchange agreement to acquire a 60% equity interest in a pioneering quantum computing bio data company ("The Target Company") for aggregate consideration of up to $54 million. The Target Company specializes in utilizing quantum computing principles to store, manipulate, and analyze BIO data more efficiently than current technologies, offering groundbreaking advancements in biological data processing and analytics.

TORONTO and GLIL YAM, Israel , Sept. 16, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (Nasdaq: IMCC), a leading medical cannabis company with operations in Israel and Germany, today announced the following changes to its Board of Directors (the "Board").

TORONTO and GLIL YAM, Israel , Sept. 5, 2025 /PRNewswire/ -- IM Cannabis Corp. (NASDAQ: IMCC) (the "Company", "IM Cannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, today announced that it received notice from Nasdaq on September 4, 2025 that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders' equity of at least $2,500,000.

TORONTO and GLIL YAM, Israel , Aug. 13, 2025 /PRNewswire/ -- IM Cannabis Corp. ("IM Cannabis" or the "Company") (NASDAQ: IMCC), a leading medical cannabis company with operations in Israel and Germany, announces that it has agreed with holders (each, a "Holder") of common share purchase warrants ("November 2024  Warrants") issued by the Company as part of its non-brokered private placement offering which closed on November 12, 2024 to: (x) reduce the exercise price of each November 2024 Warrant from C$4.32 to C$3.43; and (y) extend the expiration date of each November 2024 Warrant from November 12, 2026 to July 31, 2030 (together, the "Transaction"). Form F-3 Resale Registration Statement The Company also announces that, further to its press release dated July 31, 2025 (the " July 31 Release"), it has filed a resale registration statement on Form F-3 (the "Resale Registration Statement") with the Securities and Exchange Commission (the "SEC").

IMC Delivers Strong Profit and Margin Growth Despite Revenue Impact from External Challenges in Q2 2025 TORONTO and GLIL YAM, Israel , Aug. 12, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ: IMCC), an international medical cannabis company, announced its financial results today for the second quarter ended June 30, 2025. All amounts are reported in Canadian dollars and compared to the quarter ended June 30, 2024, unless otherwise stated.

TORONTO and GLIL YAM, Israel , Aug. 4, 2025 /PRNewswire/ -- IM Cannabis Corp. (NASDAQ: IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the second quarter 2025 ended June 30, 2025, on Tuesday, August 12, 2025, before the market opens.   About IM Cannabis Corp. IMC (Nasdaq: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets.